Accused of trying to delay in launch of Hypertension drug generic, Novartis settles litigation with payment of Rs 2028 crore Ruchika Sharma29 Dec 2022 8:45 AMNovartis and Par were accused of entering an illegal "reverse payment" agreement to delay launches of less expensive, generic versions of Exforge,...
Novartis gets CDSCO panel nod to study anticancer drug JDQ443 Dr. Divya Colin17 Dec 2022 12:30 PMNew Delhi: Pharmaceutical major Novartis, has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Novartis prostate cancer therapy Pluvicto bags European Commission nod Ruchika Sharma14 Dec 2022 10:45 AM"The approval of Pluvicto by the European Commission marks a major milestone for patients with advanced prostate cancer who have few alternative...
Novartis considers selling ophthalmology, respiratory units to invest in cutting-edge medicines Ruchika Sharma17 Nov 2022 6:45 AMAny sale of the ophthalmology and respiratory businesses is likely to begin in 2023, after the process for Sandoz is completed, the Bloomberg report...
Novartis allows generic Leukemia drug production in 7 nations: Bloomberg Ruchika Sharma21 Oct 2022 9:05 AMChronic myeloid leukemia is a cancer that starts in the blood-forming cells found in bone marrow, before spilling into the general blood stream.
Novartis gets positive EMA panel opinion for prostate cancer drug Pluvicto Ruchika Sharma17 Oct 2022 6:02 AMPluvicto is a radioligand therapy combining a targeting compound (ligand, in this case directed to PSMA) with a therapeutic radioisotope
US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics Ruchika Sharma15 Oct 2022 8:00 AMNovartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patent's 2027 expiration.
Novartis to prioritise US market, unfazed by drug pricing pushback Ruchika Sharma25 Sept 2022 9:21 AMNovartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.
Novartis to take US drug patent case to Supreme Court Ruchika Sharma22 Sept 2022 10:16 AMZurich: Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug...
Novartis under Swiss competition commission radar over unlawful use of patent Ruchika Sharma16 Sept 2022 2:00 PMNovartis said COMCO had started an investigation in collaboration with the European Commission into the assertion of a patent in the broader field of...
Whistleblower case alleging kickback for promotion of Novartis MS drug Gilenya dismissed Ruchika Sharma14 Sept 2022 9:00 AMNovartis moved to dismiss, arguing that Camburn still had not offered enough detail to support his claim of a fraudulent scheme.
Cosentyx shows clinically meaningful symptom improvements in patients with painful skin condition in pivotal Phase III trials: Novartis Ruchika Sharma12 Sept 2022 9:30 AMHidradenitis Suppurativa is a chronic, inflammatory, debilitating skin condition with systemic comorbidities that has a profoundly negative effect on...
